



Montana Healthcare Programs Drug Prior Authorization Coverage Criteria

Xarelto™ (rivaroxaban)

Review Criteria

Member must meet all the following criteria:

- Subject to Preferred Drug List requirements
- 2.5 mg dose requires diagnosis of either chronic coronary artery disease (CAD) or peripheral artery/vascular disease (PAD/PVD)
 - Used in combination with ASA at this low dose
 - Max dose is 2.0
- Xarelto Suspension may be approved for pediatric patients requiring **under 10 mg per dose** for the following indications:
 - Treatment of VTE and reduction in risk of recurrent VTE in pediatric patients from birth to less than 18 years of age.
 - Max dose is weight based per FDA-approved dosage:

Dosage Form	Body Weight	1mg XARELTO = 1 mL Suspension			
		Dosage			Total Daily Dose
		Once a Day	2 Times a Day	3 Times a Day	
Oral Suspension Only	2.6 kg to 2.9 kg			0.8 mg	2.4 mg
	3 kg to 3.9 kg			0.9 mg	2.7 mg
	4 kg to 4.9 kg			1.4 mg	4.2 mg
	5 kg to 6.9 kg			1.6 mg	4.8 mg
	7 kg to 7.9 kg			1.8 mg	5.4 mg
	8 kg to 8.9 kg			2.4 mg	7.2 mg
	9 kg to 9.9 kg			2.8 mg	8.4 mg
	10 kg to 11.9 kg			3 mg	9 mg
Oral Suspension or Tablets	12 kg to 29.9 kg		5 mg		10mg
	30 kg to 49.9 kg	15 mg			15 mg
	≥50 kg	20 mg			20mg

- Thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure.
- Max dose is weight based per FDA-approved dosage:

Dosage Form	Body Weight	1mg XARELTO = 1 mL Suspension		
		Dosage		Total Daily Dose
		Once a Day	2 Times a Day	
Oral Suspension Only	7 kg to 7.9 kg		1.1 mg	2.2 mg
	8 kg to 9.9 kg		1.6 mg	3.2 mg
	10 kg to 11.9 kg		1.7 mg	3.4 mg
	12 kg to 19.9 kg		2 mg	4 mg
	20 kg to 29.9 kg		2.5 mg	5 mg
	30 kg to 49.9 kg	7.5 mg		7.5mg
Oral Suspension or Tablets	≥50 kg	10 mg		10mg